Allergic rhinitis in Latin America: knowledge, attitudes, and clinical practices of specialists in allergy and clinical immunology— CAPRA-SLAAI study
Main Article Content
Keywords
Allergic rhinitis, attittudes, clinical health
Abstract
Allergic rhinitis (AR) is highly prevalent in Latin America (LA), impairing quality of life and often coexisting with asthma. In spite of dissemination of international guidelines, regional differences in diagnosis and management persist. The “Conductas, Actitudes y Prácticas de la Sociedad Latinoamericana de Alergia e Inmunología” (CAPRA–SLAAI) study aimed to assess the knowledge, attitudes, and practices on AR of allergists and clinical immunologists affiliated with SLAAI. Between November 2022 and March 2023, a standardized ARIA-adapted questionnaire (validated in Spanish/Portuguese) was distributed online to specialists from 24 countries; 784 were eligible for analysis. Nearly three-quarters were from Brazil (49.7%) and Mexico (25.8%), with a mean age of 50 years. Awareness of ARIA guidelines was almost universal; however, only 41% knew the MASK-air® digital tool, and fewer than 12% reported regular use, with low uptake in Brazil. Brazilian (BR) specialists more often reported extra-nasal symptoms and greater impact on daily activities, suggesting differences in presentation or reporting. Diagnostic strategies varied: BRs relied more on serum IgE and anterior rhinoscopy, whereas others used skin tests and imaging. Pharmacological treatment was similar across LA, with the use of second-generation antihistamines and intranasal corticosteroids. Immunotherapy approaches differed: subcutaneous and sublingual immunotherapy were more common outside BR, where pollinosis results in a greater variety of extracts. Conversely, allergen extracts are more standardized in Brazil. This survey reveals important regional contrasts and underscores the need for training, access to diagnostic tools, harmonized strategies, and greater integration of digital health solutions to optimize AR management in LA.
References
2. Strachan DP, Rutter CE, Asher MI, Bissel K, Chiang CY, Sony AE, et al. Worldwide time trends in prevalence of symptoms of rhinoconjunctivitis in children: global asthma network phase I. Pediatr. Allergy Immunol. 2022;33(1):e13656.https:// doi.org/10.1111/pai.13656
3. Mortimer K, Lesosky M, Garcia-Marcos L, Asher MI, Pearce N, Ellwood E, et al. The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study. Eur. Respir. J. 2022;60(3):2102865. https://doi. org/10.1183/13993003.02865-2021
4. Urrutia-Pereira M, Mocelin LP, Ellwood P, Garcia-Marcos L, Simon L, Rinelli P, et al. Rev. Paul. Pediatr. 2023;41:e2021400. https://doi.org/10.1590/1984-0462/2023/41/2021400
5. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic rhinitis and its Impact on asthma (ARIA) guidelines—2016 revision. Allergy Clin. Immunol. 2017;140(4):950–958. https://doi.org/10.1016/j.jaci.2017.03.050
6. Neffen H, Mello Jr JF, Solé D, Naspitz CK, Dodero AE, Garza HL, et al. Nasal allergies in the Latin American pop-ulation: results from the allergies in Latin America survey. Allergy Asthma Proc. 2010:31(Suppl 1):S9–27. https://doi. org/10.2500/aap.2010.31.3347
7. Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK, et al. Burden of allergic rhinitis: results from the pediatric allergies in America survey. J. Allergy Clin. Immunol. 2009;124(3 Suppl):S43–70. https://doi. org/10.1016/j.jaci.2009.05.013
8. Scadding GK, Smith PK, Blaiss M, Roberts G, Hellings PW, Gevaert P, et al. Allergic rhinitis in childhood and the new EUFOREA algorithm. Front. Allergy. 2021 Jul 14;2:706589. https://doi.org/10.3389/falgy.2021.706589
9. Nasa P, Jain R, Juneja D. Delphi methodology in health-care research: how to decide its appropriateness. World J. Methodol. 2021 Jul 20;11(4):116–129. https://doi.org/10.5662/ wjm.v11.i4.116
10. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008. Allergy. 2008;63(Suppl 86):8–160. https://doi. org/10.1111/j.1398-9995.2007.01620.x
11. Bousquet J, Anto JM, Bachert C, Haahtela T, Zuberbier T, Czarlewski W et al. ARIA digital anamorphosis: digital transformation of health and care in airway diseases from research to practice. Allergy. 2021 Jan;76(1):168–190. https:// doi.org/10.1111/all.14422
12. Larenas-Linnemann D, Mullol J, Ivancevich JC, Antó JM, Cardona V, Dedeu T, et al. La solución integral de ARIA por app móvil para la multimorbilidad de rinitis alérgica y asma [MASK (Mobile Airways Sentinel Network). ARIA’s com-prehensive solution for mobile app for the multimorbidity of allergic rhinitis and asthma]. Rev. Alerg. Mex. 2019 Jan-Mar;66(1):140–146. https://doi.org/10.29262/ram.v66i1.578
13. Vélez CM, Wilson MG, Lavis JN, Abelson J, Florez ID. A framework for explaining the role of values in health policy decision-making in Latin America: a critical interpretive syn-thesis. Health Res. Policy Syst. 2020 Sep 7;18(1):100. https:// doi.org/10.1186/s12961-020-00584-y
14. Gonzalez-Diaz SN, Martin B, de Lira-Quezada CE, Villarreal-Gonzalez RV, Guzman-Avilan RI, Macías-Weinmann A, et al. Current situation of allergy education in Mexico and other parts of Latin America. World Allergy Organ. J. 2021 May 18;14(5):100543. https://doi.org/10.1016/j. waojou.2021.100543
15. Barker S, Daniels L, Chang YS, Chikovani T, DunnGalvin A, Gerdts JD, et al. World Allergy Organ. J. 2021 Nov 10;14(10):100589. https://doi.org/10.1016/j.waojou.2021.100589
16. Almeida ATC, Sá EB, Vieira FS, Benevides RPSE. Impacts of a Brazilian pharmaceutical program on the health of chronic patients. Rev. Saude. Publica. 2019 Jan 31;53:20. https://doi. org/10.11606/S1518-8787.2019053000733
17. Cardona R, Sánchez A, Larenas-Linnemann D, Járes E, Sánchez J. Extractos alergénicos para inmunoterapia en Latinoamérica [Allergen extracts for immunotherapy in Latin America]. Rev. Alerg. Mex. 2018 Jan–Mar;65(1):25–40. Spanish. https://doi.org/10.29262/ram.v65i1.287
18. Aarestrup FM, Lira GVAG, Taketomi EA, Gagete E, Rosário Filho NA, Rizzo MC, et al. Brazilian guidelines for allergen immunotherapy in the treatment of allergic rhinitis. Rev. Assoc. Med. Bras. (1992). 2023 Jun 2;69(5):e2023D695. https://doi.org/10.1590/1806-9282.2023d695
19. Larenas-Linnemann DES, Loy LC, Abdullah B, Scadding GK. Moving towards an integrated approach to allergic rhinitis management: ARIA and EUFOREA guidelines similarities and differences. Curr. Allergy Asthma Rep. 2025 Jul 24;25(1):30. https://doi.org/10.1007/s11882-025-01212-x
20. Scadding GK, Conti DM, Scheire S, Backer V, Blaiss M, Cardell LO, et al. EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR. Front. Allergy. 2025 Feb 3;5:1531788. https://doi. org/10.3389/falgy.2024.1531788
21. Bousquet J, Anto JM, Sousa-Pinto B, Czarlewski W, Bedbrook A, Haahtela T, et al. Digitally enabled, patient-centred care in rhinitis and asthma multimorbidity: the ARIA-MASK-air® approach. Clin. Transl. Allergy. 2023 Jan;13(1):e12215. https://doi.org/10.1002/clt2.12215
22. Bousquet J, Schünemann HJ, Sousa-Pinto B, Zuberbier T, Togias A, Samolinski B, et al. Concepts for the development of person-centered, digitally enabled, artificial intelligence-assisted ARIA care pathways (ARIA 2024). J. Allergy Clin. Immunol. Pract. 2024 Oct;12(10):2648–2668.e2. https:// doi.org/10.1016/j.jaip.2024.06.040
23. Bousquet J, Sousa-Pinto B, Anto JM, Bedbrook A, Fonseca JA, Zuberbier T; MASK-air Think Tank. MASK-air: An OECD (Organisation for Economic Co-operation and Development) best practice for public health on integrated care for chronic diseases. J. Allergy Clin. Immunol. Pract. 2024 Aug;12(8):2010–2016.e7. https://doi.org/10.1016/j.jaip.2024. 03.024. Epub 2024 Mar 21.